Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2018 07:00 ET | Source: uniQure Inc.

uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
June 13, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces New Appointments to its Board of Directors

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, June 13, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
May 29, 2018 07:00 ET | Source: uniQure Inc.

uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy

~ Newly Issued Patents in the U.S. and Canada Cover Methods of Treating Hemophilia B and Other Bleeding Disorders using FIX-Padua in AAV Gene Therapy ~ ~ Additional Issued Patent Covering...
May 21, 2018 07:00 ET | Source: uniQure Inc.

uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies

-- New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 -- -- Data Suggest AAV5 Gene Therapies May be Viable Treatments for at Least 97% of Patients -- -- Data Presented at the...
May 18, 2018 07:00 ET | Source: uniQure Inc.

uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy

-- Preclinical Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Chicago -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 18, 2018 (GLOBE NEWSWIRE)...
May 07, 2018 11:47 ET | Source: uniQure Inc.

uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 07, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with...
May 02, 2018 19:32 ET | Source: uniQure Inc.

uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 02, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with...
May 01, 2018 16:04 ET | Source: uniQure Inc.

uniQure Announces Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 30, 2018 12:00 ET | Source: uniQure Inc.

uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 to be Featured in Oral Presentation LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 30, 2018 (GLOBE NEWSWIRE) --...
April 30, 2018 07:05 ET | Source: uniQure Inc.

uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress

~ Patient enrollment expected to begin ahead of schedule in dose-confirmation study for AMT-061 and pivotal study on track to commence in third quarter of 2018 ~ IND filing for AMT-130 in...